{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:32Z","timestamp":1787003672782,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["M2R201806006018"],"award-info":[{"award-number":["M2R201806006018"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13160-7","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:38:56Z","timestamp":1759844336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Olivier","family":"Caliez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Doat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pietrasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"13160_CR1","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","volume":"55","author":"J Ferlay","year":"2016","unstructured":"Ferlay, J., Partensky, C. & Bray, F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 55, 1158\u20131160 (2016).","journal-title":"Acta Oncol."},{"key":"13160_CR2","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA: A Cancer J. Clin."},{"key":"13160_CR3","first-page":"1817","volume":"9","author":"C Thierry","year":"2011","unstructured":"Thierry, C. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 9, 1817 (2011).","journal-title":"N. Engl. J. Med."},{"key":"13160_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased Survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"13160_CR5","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19\u20139 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. 3, 105\u2013119 (2012).","journal-title":"J. Gastrointest. Oncol."},{"key":"13160_CR6","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1038\/ncomms8686","volume":"6","author":"M Sausen","year":"2015","unstructured":"Sausen, M. et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 6, 7686 (2015).","journal-title":"Nat. Commun."},{"key":"13160_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0950","author":"J-B Bachet","year":"2020","unstructured":"Bachet, J.-B. et al. Circulating tumor DNA is prognostic and potentially predictive of eryaspase efficacy in second-line in patients with advanced pancreatic adenocarcinoma. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0950 (2020).","journal-title":"Clin. Cancer Res."},{"key":"13160_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.gene.2018.09.029","volume":"679","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis. Gene 679, 328\u2013334 (2018).","journal-title":"Gene"},{"key":"13160_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1158\/1078-0432.CCR-16-0806","volume":"23","author":"D Pietrasz","year":"2017","unstructured":"Pietrasz, D. et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin. Cancer Res. 23, 116\u2013123 (2017).","journal-title":"Clin. Cancer Res."},{"key":"13160_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz, D. et al. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: Post-hoc analyses of two clinical trials. Br. J. Cancer 126, 440\u2013448 (2022).","journal-title":"Br. J. Cancer"},{"key":"13160_CR11","doi-asserted-by":"publisher","first-page":"11610","DOI":"10.1038\/s41598-019-47489-7","volume":"9","author":"S Mohan","year":"2019","unstructured":"Mohan, S. et al. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in pancreatic cancer. Sci. Rep. 9, 11610 (2019).","journal-title":"Sci. Rep."},{"key":"13160_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-019-0824-4","volume":"12","author":"H Patel","year":"2019","unstructured":"Patel, H. et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J. Hematol. Oncol. 12, 130 (2019).","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"13160_CR13","doi-asserted-by":"publisher","first-page":"00138","DOI":"10.1016\/j.dld.2022.01.126","volume":"S1590\u20138658","author":"O Caliez","year":"2022","unstructured":"Caliez, O. et al. Circulating tumor DNA: A help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?. Dig. Liver Dis. S1590\u20138658(22), 00138\u201300144. https:\/\/doi.org\/10.1016\/j.dld.2022.01.126 (2022).","journal-title":"Dig. Liver Dis."},{"key":"13160_CR14","unstructured":"Strijker, M. et al. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int. J. Cancer"},{"key":"13160_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232674","volume":"313","author":"L Dawi","year":"2024","unstructured":"Dawi, L. et al. Liquid biopsy versus CT: Comparison of tumor burden quantification in 1065 patients with metastases. Radiology 313, e232674 (2024).","journal-title":"Radiology"},{"key":"13160_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccr.2014.05.026","volume":"25","author":"J Gore","year":"2014","unstructured":"Gore, J. & Korc, M. Pancreatic cancer stroma: Friend or foe?. Cancer Cell 25, 711\u2013712 (2014).","journal-title":"Cancer Cell"},{"key":"13160_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","volume":"156","author":"V Bernard","year":"2019","unstructured":"Bernard, V. et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology 156, 108-118.e4 (2019).","journal-title":"Gastroenterology"},{"key":"13160_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2008.03.001","volume":"68","author":"S Mulero-Navarro","year":"2008","unstructured":"Mulero-Navarro, S. & Esteller, M. Epigenetic biomarkers for human cancer: The time is now. Crit. Rev. Oncol. Hematol. 68, 1\u201311 (2008).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"13160_CR19","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-17-0510","volume":"23","author":"LV Sch\u00f8ler","year":"2017","unstructured":"Sch\u00f8ler, L. V. et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin. Cancer Res. 23, 5437\u20135445 (2017).","journal-title":"Clin. Cancer Res."},{"key":"13160_CR20","doi-asserted-by":"publisher","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","volume":"13","author":"CA Parkinson","year":"2016","unstructured":"Parkinson, C. A. et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: A retrospective study. PLoS Med. 13, e1002198 (2016).","journal-title":"PLoS Med."},{"key":"13160_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ejso.2021.11.138","volume":"48","author":"P Kirchweger","year":"2022","unstructured":"Kirchweger, P. et al. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage. Eur. J. Surg. Oncol. 48, 1046\u20131053 (2022).","journal-title":"Eur. J. Surg. Oncol."},{"key":"13160_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/annonc\/mdy061","volume":"29","author":"JB Bachet","year":"2018","unstructured":"Bachet, J. B. et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann. Oncol. 29, 1211\u20131219 (2018).","journal-title":"Ann. Oncol."},{"key":"13160_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac214","author":"C Nitschke","year":"2023","unstructured":"Nitschke, C. et al. Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumor recurrence in pancreatic ductal adenocarcinoma. Clin. Chem. https:\/\/doi.org\/10.1093\/clinchem\/hvac214 (2023).","journal-title":"Clin. Chem."},{"key":"13160_CR24","doi-asserted-by":"publisher","unstructured":"Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer|Elsevier Enhanced Reader. https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S2589004222000967?token=2189474A585606D5BFD521E32294A56FA015AE70A75A4EB60947EE8A178AB05409A5B9784038B2DD84B944AE973FF6C3&originRegion=eu-west-1&originCreation=20230212103135https:\/\/doi.org\/10.1016\/j.isci.2022.103826.","DOI":"10.1016\/j.isci.2022.103826"},{"key":"13160_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1593\/tlo.09256","volume":"3","author":"AS Ho","year":"2010","unstructured":"Ho, A. S. et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3, 109\u2013113 (2010).","journal-title":"Transl Oncol"},{"key":"13160_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","volume":"23","author":"R Perets","year":"2018","unstructured":"Perets, R. et al. Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. Oncologist 23, 566\u2013572 (2018).","journal-title":"Oncologist"},{"key":"13160_CR27","doi-asserted-by":"publisher","first-page":"112934","DOI":"10.1016\/j.ejca.2023.05.022","volume":"189","author":"J-B Bachet","year":"2023","unstructured":"Bachet, J.-B. et al. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-na\u00efve metastatic colorectal cancer. An AGEO prospective study. Eur. J. Cancer 189, 112934 (2023).","journal-title":"Eur. J. Cancer"},{"key":"13160_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone, C. R. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg. 261, 12\u201317 (2015).","journal-title":"Ann. Surg."},{"key":"13160_CR29","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1007\/s00330-016-4632-8","volume":"27","author":"M Wagner","year":"2017","unstructured":"Wagner, M. et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur. Radiol. 27, 3104\u20133116 (2017).","journal-title":"Eur. Radiol."},{"key":"13160_CR30","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","volume":"29","author":"S Kruger","year":"2018","unstructured":"Kruger, S. et al. Repeated mut KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann. Oncol. 29, 2348\u20132355 (2018).","journal-title":"Ann. Oncol."},{"key":"13160_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14245","author":"M Sugimori","year":"2019","unstructured":"Sugimori, M. et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.14245 (2019).","journal-title":"Cancer Sci."},{"key":"13160_CR32","unstructured":"Wang-Renault, S., Pietrasz, D., Bachet, J.-B., Puig, P. L. & Taly, V. Detection of hypermethylated genes for diagnosing pancreatic cancer (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13160-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T13:38:59Z","timestamp":1759844339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13160-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13160-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6422905\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34865"}}